WHO Grade II Glioma Clinical Trial
Official title:
A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04479696 -
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
|
N/A | |
Recruiting |
NCT03251027 -
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
|
N/A | |
Recruiting |
NCT04623931 -
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
|
Phase 2 | |
Recruiting |
NCT04540107 -
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
|
Phase 1 | |
Recruiting |
NCT03749187 -
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
|
Phase 1 |